Search
Tempest Therapeutics Inc
TPSTAdd to Watchlist
0.496USD
-0.037-6.94%
Close 10-30 16:00（ET）
8.38MMarket Cap
0.02P/E TTM
After-hours 16:33 (ET)0.502USD-0.002-0.40%
After-hours 16:33 (ET)About Tempest Therapeutics Inc Company
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Tempest Therapeutics Inc Profile
Ticker SymbolTPST
Company nameTempest Therapeutics Inc
IPO dateOct 04, 2012
CEO- -
Number of employees24
Security typeOrdinary Share
Fiscal year-endOct 04
Address2000 Sierra Point Parkway
CityBRISBANE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94005
Phone14157988589
Websitehttps://www.tempesttx.com/
Ticker SymbolTPST
IPO dateOct 04, 2012
CEO- -
Company Executives of Tempest Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Matthew (Matt) Angel, Ph.D.
Dr. Matthew (Matt) Angel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.07M
--
Dr. Matthew (Matt) Angel, Ph.D.
Dr. Matthew (Matt) Angel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.07M
--
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
666.00
--
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
590.00
--
Dr. Samuel (Sam) Whiting, M.D., Ph.D.
Dr. Samuel (Sam) Whiting, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
-100.00%
Dr. John David Yee, M.D.
Dr. John David Yee, M.D.
Independent Director
Independent Director
--
--
Mr. William Drake Richey
Mr. William Drake Richey
Independent Director
Independent Director
--
--
Ms. Nancy Freda-Smith, CPA
Ms. Nancy Freda-Smith, CPA
Director
Director
--
--
Constance Ames
Constance Ames
Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, Corporate Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Matthew (Matt) Angel, Ph.D.
Dr. Matthew (Matt) Angel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.07M
--
Dr. Matthew (Matt) Angel, Ph.D.
Dr. Matthew (Matt) Angel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
5.07M
--
Mr. Stephen R. Brady
Mr. Stephen R. Brady
President, Principal Executive Officer, Director
President, Principal Executive Officer, Director
3.61K
--
Dr. Geoffrey M. (Geoff) Nichol
Dr. Geoffrey M. (Geoff) Nichol
Independent Director
Independent Director
666.00
--
Mr. Nicholas Maestas
Mr. Nicholas Maestas
Principal Financial Officer
Principal Financial Officer
590.00
--
Dr. Samuel (Sam) Whiting, M.D., Ph.D.
Dr. Samuel (Sam) Whiting, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
-100.00%
FAQs
Who are the top five shareholders of Tempest Therapeutics Inc?
The top five shareholders of Tempest Therapeutics Inc are: Dr. Matthew (Matt) Angel, Ph.D.
How many institutions hold shares of Tempest Therapeutics Inc (TPST)?
As of 2026Q1, 68 institutions hold shares of Tempest Therapeutics Inc, with a combined market value of approximately 4.51M, accounting for 31.43% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 3582210.00.